FDA Drug recall D-168-2013
EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltrati…
- FDA Drug
- Class II
- terminated
- Published 2013-03-06
On 2013-03-06 the FDA classified a Class II recall of EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltrati… by Pacira Pharmaceuticals, citing subpotent; bupivacaine.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-168-2013 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2012-12-17 |
| Published | 2013-03-06 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Pacira Pharmaceuticals |
| Distribution | US |
Product
EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA
Reason
Subpotent; bupivacaine
Identifiers
| code_info | Lot #11-2005 Control #23542 Manufacture Date: 05Dec11 2011-L-009 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-168-2013%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.